Home/Pipeline/COBENFY (xanomeline/trospium)

COBENFY (xanomeline/trospium)

Schizophrenia

ApprovedApproved in China (Dec 2025)

Key Facts

Indication

Schizophrenia

Phase

Approved

Status

Approved in China (Dec 2025)

Company

Zai Lab

About Zai Lab

Zai Lab is a patient-focused, global biopharma founded in 2014 with a mission to bridge scientific innovation from the West with deep market access and development capabilities in Greater China. The company has established itself as a fully integrated organization with eight commercialized products in China and a promising pipeline of internally discovered and in-licensed assets. Its core strategy combines a hybrid business model of strategic partnerships and internal R&D to address significant unmet medical needs across its core therapeutic areas.

View full company profile

Therapeutic Areas

Oncology Immunology Neuroscience Infectious Disease

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
Schizophrenia Candidate	Teva	Phase 3	Active
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active